Literature DB >> 3408637

Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.

K F Whyte1, C Reid, G J Addis, R Whitesmith, J L Reid.   

Abstract

1. We have previously shown that salbutamol induced hypokalaemia, like adrenaline induced hypokalaemia, is the result of stimulation of a membrane bound beta 2-adrenoreceptor linked to Na+/K+ ATPase. We have also demonstrated that adrenaline induced hypokalaemia is potentiated by therapeutic concentrations of theophylline. 2. In a single-blind study of 14 normal volunteers, we infused salbutamol in doses used in clinical practice and examined the effects of the addition of theophylline alone or combined with (-)-adrenaline on plasma potassium levels, heart rate and blood pressure. The combinations studied were (i) salbutamol + vehicle control adrenaline infusion + placebo theophylline; (ii) salbutamol + vehicle control adrenaline infusion + theophylline; (iii) salbutamol + adrenaline + theophylline. 3. In a randomised, balanced placebo controlled design oral slow release theophylline or placebo was given for 9 days. Subjects were studied twice on the active limb (days 7 and 9) and once on the placebo limb (day 9) and the procedure was identical on each of the 3 study days except for the solutions administered. 4. Theophylline increased salbutamol induced hypokalaemia and in some individuals profound hypokalaemia (less than 2.5 mmol l-1) was observed with these relatively low doses of salbutamol and theophylline. Adrenaline did not further increase the magnitude of the fall in potassium observed. Combining theophylline with salbutamol increased the tachycardia resulting from the salbutamol infusion. Salbutamol infusion caused a fall in diastolic and rise in systolic blood pressure on all 3 study days and this was not altered by either theophylline or adrenaline alone or together.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408637      PMCID: PMC1386430          DOI: 10.1111/j.1365-2125.1988.tb03347.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The potentiation of cardiac inotropic responses to norepinephrine by theophylline.

Authors:  T W RALL; T C WEST
Journal:  J Pharmacol Exp Ther       Date:  1963-03       Impact factor: 4.030

2.  The action of adrenaline on serum potassium.

Authors:  J L D'Silva
Journal:  J Physiol       Date:  1934-11-12       Impact factor: 5.182

3.  Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.

Authors:  S R Smith; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

4.  Sequential estimation of plasma catecholamines in exercise-induced asthma.

Authors:  J Griffiths; F Y Leung; S Grzybowski; M M Chan-Yeung
Journal:  Chest       Date:  1972-11       Impact factor: 9.410

5.  Simultaneous assay of 3,4-dihydroxyphenylethylene glycol and norepinephrine in human plasma by high-performance liquid chromatography with electrochemical detection.

Authors:  L G Howes; S Miller; J L Reid
Journal:  J Chromatogr       Date:  1985-03-22

6.  Failure of chronic theophylline therapy to alter circulating catecholamines.

Authors:  K F Whyte; G J Addis; R Whitesmith; J L Reid
Journal:  Eur J Respir Dis       Date:  1987-04

7.  Enhancement of cardiotoxic effects of beta-adrenergic bronchodilators by aminophylline in experimental animals.

Authors:  X Joseph; V E Whitehurst; S Bloom; T Balazs
Journal:  Fundam Appl Toxicol       Date:  1981 Nov-Dec

8.  Circulating catecholamines in exercise and hyperventilation induced asthma.

Authors:  P J Barnes; M J Brown; M Silverman; C T Dollery
Journal:  Thorax       Date:  1981-06       Impact factor: 9.139

9.  Role of alpha- and beta-adrenergic activation in ventricular fibrillation death of corticoid-pretreated rats.

Authors:  M Green; G Guideri; D Lehr
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

10.  Circulating catecholamines in acute asthma.

Authors:  P W Ind; R C Causon; M J Brown; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-26
View more
  9 in total

Review 1.  Adverse reactions and interactions with theophylline.

Authors:  M H Skinner
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

2.  Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects.

Authors:  B J Lipworth; D G McDevitt; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

Review 3.  Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.

Authors:  D M Newnham
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  The biochemical effects of high-dose inhaled salbutamol in patients with asthma.

Authors:  B J Lipworth; R A Clark; C G Fraser; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Risks versus benefits of inhaled beta 2-agonists in the management of asthma.

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 6.  Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

Authors:  B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

7.  The dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potential.

Authors:  W J Du Plooy; L Hay; C P Kahler; P J Schutte; H D Brandt
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

8.  Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.

Authors:  K G Bauer; B Kaik; K Sertl; G A Kaik
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

Review 9.  Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Klaus J Wirth; Carmen Scheibenbogen
Journal:  J Transl Med       Date:  2021-04-21       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.